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e eﬀectiveness of anticancer treatments is oen hampered by the serious side eﬀects owing to toxicity of anticancer drugs and
their undesirable uptake by healthy cells in vivo. ermosensitive liposome-mediated drug delivery has been developed as part of
research eﬀorts aimed at improving therapeutic eﬃcacy while reducing the associated side eﬀect. Since multiple steps are involved
in the transport of drug-loaded liposomes, drug release, and its uptake, mathematical models become an indispensible tool to
analyse the transport processes and predict the outcome of anticancer treatment. In this study, a computational model is developed
which incorporates the key physical and biochemical processes involved in drug delivery and cellular uptake. e model has been
applied to idealized tumour geometry, and comparisons aremade between continuous infusion of doxorubicin and thermosensitive
liposome-mediated delivery. Results show that thermosensitive liposome-mediated delivery performs better in reducing drug
concentration in normal tissues, which may help lower the risk of associated side eﬀects. Compared with direct infusion over a
2-hour period, thermosensitive liposome delivery leads to a much higher peak intracellular concentration of doxorubicin, which
may increase cell killing in tumour thereby enhancing the therapeutic eﬀect of the drug.
1. Introduction
As a common anticancer drug, doxorubicin is widely used
in chemotherapy to treat various types of cancer, such as
lymphoma, genitourinary, thyroid, and stomach cancer [1].
By interacting with DNA in cells, doxorubicin can inhibit the
process of DNA replication. Because of this mechanism of
action, high concentration of doxorubicin in normal tissues
can cause serious damage to healthy cells, known as side
eﬀects. In clinical therapy, the most serious toxicity is life-
threatening cardiomyopathy [2, 3], leading to heart failure.
Side eﬀects set a limit to the lifetime dose a patient can receive,
which is approximately 550mg per unit body surface area
[1].
In order to improve the therapeutic bene�t while reduc-
ing toxicity of doxorubicin in normal tissues, various treat-
ment modalities have been developed. Recently, liposome-
mediated doxorubicin delivery has been proposed as an alter-
native to direct intravenous administration. Some animal
experiments have shown that liposomal doxorubicin delivery
oﬀers better eﬀectiveness of anticancer treatments than bolus
injection, but no obvious advantage over continuous infusion
was reported [4]. e development of thermosensitive lipo-
somes to enhance the eﬀectiveness of anticancer treatment
has been reported in many studies (e.g., [5–8]).
Following administration, the drug-loaded thermosensi-
tive liposome-based nanoparticles are usually small enough
to pass through the vasculature wall and then accumulate
in the extracellular space in tumour. Localised heating can
be performed several hours aer drug administration. Upon
heating to the phase transition temperature of the thermosen-
sitive liposome, the encapsulated drug can be released from
liposomes at a high rate. Some of the released drug may
bind with proteins in blood and be cleared up by blood
�ow, whereas the rest will permeate through the vasculature
wall entering the interstitial space. Drug in the interstitium
may also bind with proteins present in the interstitial �uid,
and be cleared up by the lymphatic system. Because of the
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concentration gradient at the interface between tumour and
normal tissues, drug exchange takes place between these
tissues. e extracellular drug may pass through the cell
membrane and be taken up by cells. Drug in tumour cells
can also be transported back to the extracellular space. Given
the many variables related to the properties of tumour,
normal tissues, and anticancer drugs, mathematical models
are needed to analyse the drug transport processes described
above.
Previous numerical studies of liposome-mediated drug
delivery have mainly focused on drug uptake by tumour
cells with a simpli�ed description of the transport processes
involved. Harashima et al. [9, 10] and Tsuchihashi et al.
[11] developedmathematical models for nonthermosensitive
liposomal drug delivery, without considering the interaction
between drug and proteins in blood plasma or intersti-
tial �uid. El-�areh and Secomb [12] used mathematical
models to determine tumour cell uptake of thermosensi-
tive liposome-mediated doxorubicin, but their model was
formulated on a simpli�ed tumour cord geometry, without
accounting for the in�uence of blood and lymphatic vessels
and the interstitial �uid �ow, nor drug binding with proteins.
However, each of these components may aﬀect the outcome
of anticancer therapy. Experimental results show that dox-
orubicin can easily bind with proteins [13].
In the present study, an improved mathematical model
is developed and applied to an idealized geometry consisting
of tumour and normal tissues. e model incorporates the
key physical and biochemical processes involved, including
time-dependent plasma clearance, liposome, and drug trans-
port through the blood and lymphatic vessels, extracellular
liposome, and drug transport (convection and diﬀusion),
drug binding with proteins, lymphatic drainage, interactions
with the surrounding normal tissues, and drug uptake by
tumour cells. erapeutic eﬀect is evaluated based on the
fraction of survival tumour cells by directly solving the
pharmacodynamics equation using the predicted intracel-
lular drug concentration. Comparisons are made of the
predicted eﬃcacies of direct intravenous administration and
thermosensitive liposome-mediated delivery.
2. Mathematical Models
In solid tumours, the size and branching patterns of micro-
vessels could vary considerably depending on the speci�c
tumour type and its growth stage [14]. For a solid tumour
at a speci�c stage, the distribution of blood vessels, lymphatic
vessels, and tumour cells are spatially heterogeneous. How-
ever, owing to the lack of in vivo data on the heterogeneity
of tumour vasculature, solid tumours are usually treated as
a spatially homogeneous domain [15–18]. If the simulation
window is much shorter than the growth rate of the tumour,
it would be reasonable to assume that the key modelling
parameters do not change with time in the simulation.
e mathematical equations governing the physical and
physiological processes of the liposome and drug transport
as well as the pharmacokinetics of the drug are described
below.
2.1. Interstitial Fluid Transport
2.1.1. Mass Conservation Equation. is is described by
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕
+ ∇ ⋅ 󶀡󶀡𝜕𝜕𝜌𝜌󶀱󶀱 = 󶀢󶀢𝐹𝐹𝑣𝑣 − 𝐹𝐹ly󶀲󶀲 𝜕𝜕𝜌 (1)
where 𝜕𝜕 and 𝜌𝜌 are the density and velocity of the interstitial
�uid, respectively. 𝐹𝐹𝑣𝑣 is the interstitial �uid loss from the
blood vessels per unit volume of tumour tissue, and 𝐹𝐹ly is
the �uid absorption rate by the lymphatics per unit volume
of tumour tissue. 𝐹𝐹𝑣𝑣 and 𝐹𝐹ly are given by Starling’s law
𝐹𝐹𝑣𝑣 = 𝐾𝐾𝑣𝑣
𝑆𝑆
𝑉𝑉
󶁡󶁡𝑝𝑝𝑣𝑣 − 𝑝𝑝𝑖𝑖 − 𝜎𝜎𝑇𝑇 󶀡󶀡𝜋𝜋𝑣𝑣 − 𝜋𝜋𝑖𝑖󶀱󶀱󶀱󶀱 𝜌 (2)
where 𝐾𝐾𝑣𝑣 is the hydraulic conductivity of the microvascular
wall, 𝑆𝑆𝑆𝑉𝑉 is the surface area of blood vessels per unit
volume of tumour tissue, 𝑝𝑝𝑣𝑣 and 𝑝𝑝𝑖𝑖 are the vascular and
interstitial �uid pressures, respectively, 𝜎𝜎𝑇𝑇 represents the
average osmotic re�ection coeﬃcient for plasma protein,𝜋𝜋𝑣𝑣 is
the osmotic pressure of the plasma, and𝜋𝜋𝑖𝑖 is that of interstitial
�uid.
e lymphatic drainage, 𝐹𝐹ly, is related to the pressure
diﬀerence between the interstitial �uid and lymphatics�
𝐹𝐹ly = 𝐾𝐾ly
𝑆𝑆ly
𝑉𝑉
󶀢󶀢𝑝𝑝𝑖𝑖 − 𝑝𝑝ly󶀲󶀲 𝜌 (3)
where𝐾𝐾ly is the hydraulic conductivity of the lymphatic wall,
𝑆𝑆ly𝑆𝑉𝑉 is the surface area of lymphatic vessels per unit volume
of tumour tissue, and 𝑝𝑝ly is the intralymphatic pressure.
2.1.2.MomentumConservation Equation. Since the intercap-
illary distance (33–98 𝜇𝜇m [19, 20]) is usually 2-3 orders of
magnitude smaller than the length scale for drug transport
(approximately 70mm in this study), it is reasonable to treat
the tumour and its surrounding tissues as porous media,
for which the Navier-Stokes equations are applicable. By
ignoring the gravitational eﬀect, the momentum equation is
expressed as
𝜕𝜕 󶀡󶀡𝜕𝜕𝜌𝜌󶀱󶀱
𝜕𝜕𝜕𝜕
+ ∇ ⋅ 󶀡󶀡𝜕𝜕𝜌𝜌𝜌𝜌󶀱󶀱 = −∇𝑝𝑝𝑖𝑖 + ∇ ⋅ 𝝉𝝉 + 𝝉𝝉𝜌 (4)
where 𝝉𝝉 is the stress tensor which is given by
𝝉𝝉 = 𝜇𝜇 󶁢󶁢∇𝜌𝜌 + (∇𝜌𝜌)𝑇𝑇󶁲󶁲 −
2
3
𝜇𝜇 (∇ ⋅ 𝜌𝜌) 𝐈𝐈𝜌 (5)
where 𝐈𝐈 is the unit tensor. e last term in (4), 𝝉𝝉, represents
the Darcian resistance to �uid �ow through porous media
and is given by
𝝉𝝉 = 𝐅𝐅𝜇𝜇𝜌𝜌 +
1
2
𝐂𝐂𝜕𝜕 |𝜌𝜌| 𝜌𝜌𝜌 (6)
and 𝐅𝐅 is a diagonal matrix with all diagonal elements
calculated as
W= 𝜅𝜅−1𝜌 (7)
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where 𝜇𝜇 is the dynamic viscosity of interstitial �uid, 𝐂𝐂 is
the prescribed matrix of the inertial loss term, and 𝜅𝜅 is the
permeability of the interstitial space. Since the velocity of
interstitial �uid is very slow (|𝐯𝐯| 𝐯 𝐯) [15], the inertial
loss term can be neglected when compared to the Darcian
resistance. �n addition, the interstitial �uid is treated as
incompressible with a constant viscosity. Hence, (6) can be
reduced to
𝐅𝐅 𝐅 𝐅𝐅𝜇𝜇𝐯𝐯𝐅 (8)
2.2. Drug Transport. Drug transport is described by equa-
tions for the free and bound drug concentrations in the
interstitial �uid and the intracellular concentration.
2.2.1. Free Doxorubicin Concentration in the Interstitial Fluid
(𝐶𝐶𝑓𝑓𝑓𝑓). is is described by
𝜕𝜕𝐶𝐶𝑓𝑓𝑓𝑓
𝜕𝜕𝜕𝜕
+ ∇ ⋅ 󶀢󶀢𝐶𝐶𝑓𝑓𝑓𝑓𝐯𝐯󶀲󶀲 𝐅 𝐷𝐷𝑓𝑓𝑓𝑓∇
2𝐶𝐶𝑓𝑓𝑓𝑓 + 𝑆𝑆𝑖𝑖, (9)
where𝐷𝐷𝑓𝑓𝑓𝑓 is the diﬀusion coeﬃcient of free doxorubicin.e
source term, 𝑆𝑆𝑖𝑖, is the net rate of doxorubicin gained from the
surrounding environment, which is given by
𝑆𝑆𝑖𝑖 𝐅 𝑆𝑆𝑣𝑣 + 𝑆𝑆𝑏𝑏 + 𝑆𝑆𝑢𝑢, (10)
𝑆𝑆𝑣𝑣, 𝑆𝑆𝑏𝑏, and 𝑆𝑆𝑢𝑢 represent the net doxorubicin gained from the
blood/lymphatic vessels, association/dissociationwith bound
doxorubicin-protein, and in�ux/eﬄux from tumour cells,
respectively,
𝑆𝑆𝑣𝑣 𝐅 𝐹𝐹𝑓𝑓𝑓𝑓 − 𝐹𝐹𝑓𝑓𝑓𝑓, (11)
where 𝐹𝐹𝑓𝑓𝑓𝑓 is the doxorubicin gained from the blood capillar-
ies in tumour and normal tissues, and 𝐹𝐹𝑓𝑓𝑓𝑓 is the doxorubicin
loss to the lymphatic vessels per unit volume of tissue. Using
the pore model [15–17, 21] for transcapillary exchange, 𝐹𝐹𝑓𝑓𝑓𝑓
and 𝐹𝐹𝑓𝑓𝑓𝑓 can be expressed as
𝐹𝐹𝑓𝑓𝑓𝑓 𝐅 𝐹𝐹𝑣𝑣 󶀡󶀡𝐯 − 𝜎𝜎𝑑𝑑󶀱󶀱𝐶𝐶𝑓𝑓𝑓𝑓 + 𝑃𝑃𝑓𝑓𝑓𝑓
𝑆𝑆
𝑉𝑉
󶀢󶀢𝐶𝐶𝑓𝑓𝑓𝑓 − 𝐶𝐶𝑓𝑓𝑓𝑓󶀲󶀲
Pe𝑓𝑓
𝑓𝑓Pe𝑓𝑓 − 𝐯
,
𝐹𝐹𝑓𝑓𝑓𝑓 𝐅 𝐹𝐹ly𝐶𝐶𝑓𝑓𝑓𝑓,
(12)
where 𝐶𝐶𝑓𝑓𝑓𝑓 is the concentration of doxorubicin in blood
plasma, 𝜎𝜎𝑑𝑑 is the osmotic re�ection coeﬃcient for the drug
molecules, and 𝑃𝑃𝑓𝑓𝑓𝑓 is the permeability of vasculature wall
to free doxorubicin. Pe𝑓𝑓 is the transcapillary Peclet number
de�ned as
Pe𝑓𝑓 𝐅
𝐹𝐹𝑣𝑣 󶀡󶀡𝐯 − 𝜎𝜎𝑑𝑑󶀱󶀱
𝑃𝑃𝑓𝑓𝑓𝑓 (𝑆𝑆𝑆𝑉𝑉)
𝐅 (13)
e net doxorubicin gained due to protein binding and
cellular uptake is governed by (14), where 𝐷𝐷𝑐𝑐 is the tumour
cell density; 𝑘𝑘𝑎𝑎 and 𝑘𝑘𝑑𝑑 are the doxorubicin-protein binding
and dissociation rates, respectively:
𝑆𝑆𝑏𝑏 𝐅 𝑘𝑘𝑑𝑑𝐶𝐶𝑏𝑏𝑓𝑓 − 𝑘𝑘𝑎𝑎𝐶𝐶𝑓𝑓𝑓𝑓,
𝑆𝑆𝑢𝑢 𝐅 𝐷𝐷𝑐𝑐𝜀𝜀 − 𝐷𝐷𝑐𝑐𝜁𝜁𝐅
(14)
2.2.2. Bound-Doxorubicin Concentration in Interstitial Fluid
(𝐶𝐶𝑏𝑏𝑓𝑓). is is described by
𝜕𝜕𝐶𝐶𝑏𝑏𝑓𝑓
𝜕𝜕𝜕𝜕
+ ∇ ⋅ 󶀡󶀡𝐶𝐶𝑏𝑏𝑓𝑓𝐯𝐯󶀱󶀱 𝐅 𝐷𝐷𝑏𝑏𝑓𝑓∇
2𝐶𝐶𝑏𝑏𝑓𝑓 + 𝐹𝐹𝑏𝑏𝑓𝑓 − 𝑆𝑆𝑏𝑏, (15)
where 𝐷𝐷𝑏𝑏𝑓𝑓 is the diﬀusion coeﬃcient of the bound dox-
orubicin-protein. 𝐹𝐹𝑏𝑏𝑓𝑓 represents the bound doxorubicin
crossing the capillary wall into the interstitial �uid, which is
given by
𝐹𝐹𝑏𝑏𝑓𝑓 𝐅 𝐹𝐹𝑣𝑣 󶀡󶀡𝐯 − 𝜎𝜎𝑑𝑑󶀱󶀱𝐶𝐶𝑏𝑏𝑓𝑓 + 𝑃𝑃𝑏𝑏𝑓𝑓
𝑆𝑆
𝑉𝑉
󶀢󶀢𝐶𝐶𝑏𝑏𝑓𝑓 − 𝐶𝐶𝑏𝑏𝑓𝑓󶀲󶀲
Pe𝑏𝑏
𝑓𝑓Pe𝑏𝑏 − 𝐯
, (16)
where 𝑃𝑃𝑏𝑏𝑓𝑓 is the permeability of vasculature wall to bound
doxorubicin, and 𝐶𝐶𝑏𝑏𝑓𝑓 is the bound doxorubicin concentra-
tion in plasma. e transcapillary Peclet number is
Pe𝑏𝑏 𝐅
𝐹𝐹𝑣𝑣 󶀡󶀡𝐯 − 𝜎𝜎𝑑𝑑󶀱󶀱
𝑃𝑃𝑏𝑏𝑓𝑓 (𝑆𝑆𝑆𝑉𝑉)
𝐅 (17)
2.2.3. Intracellular Doxorubicin Concentration (𝐶𝐶𝑖𝑖). Because
mainly free doxorubicin can pass through the cell membrane
and enter the intracellular space [12], the rate of cellular
uptake is a function of free doxorubicin concentration in the
interstitial �uid:
𝜕𝜕𝐶𝐶𝑖𝑖
𝜕𝜕𝜕𝜕
𝐅 𝜁𝜁 − 𝜀𝜀,
𝜁𝜁 𝐅 𝑉𝑉max
𝐶𝐶𝑓𝑓𝑓𝑓
𝐶𝐶𝑓𝑓𝑓𝑓 + 𝑘𝑘𝑓𝑓𝜑𝜑
,
𝜀𝜀 𝐅 𝑉𝑉max
𝐶𝐶𝑖𝑖
𝐶𝐶𝑖𝑖 + 𝑘𝑘𝑖𝑖
,
(18)
where 𝑉𝑉max is the rate of transmembrane transport, 𝜁𝜁 and
𝜀𝜀 are cellular uptake and eﬄux functions, 𝑘𝑘𝑓𝑓 and 𝑘𝑘𝑖𝑖 are
constants obtained from experimental data �tting, and 𝜑𝜑 is
the volume fraction of extracellular space.
2.3. ermosensitive Liposome-Mediated Drug Transport.
Equations describing the transport of liposome-mediated
drug include encapsulated drug concentration in the intersti-
tial �uid, and released doxorubicin in plasma and interstitial
�uid. Equations for drug transport include those for free
drug concentration in plasma and interstitial �uid. Bound
drug concentration in plasma and interstitial �uid as well
as intracellular concentration are described using the same
equations given in the preceding section.
2.3.1. Liposome Encapsulated Drug Concentration in the
Interstitial Fluid (𝐶𝐶𝑓𝑓𝑓𝑓). is is described by
𝜕𝜕𝐶𝐶𝑓𝑓𝑓𝑓
𝜕𝜕𝜕𝜕
+ ∇ ⋅ 󶀡󶀡𝐶𝐶𝑓𝑓𝑓𝑓𝐯𝐯󶀱󶀱 𝐅 𝐷𝐷𝑓𝑓∇
2𝐶𝐶𝑓𝑓𝑓𝑓 + 𝑆𝑆𝑓𝑓, (19)
where𝐷𝐷𝑓𝑓 is the diﬀusion coeﬃcient of liposome encapsulated
drug. e source term 𝑆𝑆𝑓𝑓 is the net rate of liposome encapsu-
lated drug gained from the surrounding environment, which
is given by
𝑆𝑆𝑓𝑓 𝐅 𝑆𝑆𝑓𝑓𝑓𝑓 − 𝑆𝑆𝑟𝑟𝐅 (20)
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𝑆𝑆𝑙𝑙𝑙𝑙 is the amount of liposome encapsulated drug fromplasma.
𝑆𝑆𝑟𝑟 represents released drug in the interstitial �uid:
𝑆𝑆𝑙𝑙𝑙𝑙 = 𝐹𝐹𝑙𝑙𝑙𝑙 − 𝐹𝐹𝑙𝑙𝑙𝑙, (21)
where 𝐹𝐹𝑙𝑙𝑙𝑙 is the liposome encapsulated doxorubicin gained
from the capillaries in tumour and normal tissues, and 𝐹𝐹𝑙𝑙𝑙𝑙
is the loss of liposome encapsulated doxorubicin through
the lymphatic vessels per unit volume of tissue. Using the
pore model for transcapillary exchange, 𝐹𝐹𝑙𝑙𝑙𝑙 and 𝐹𝐹𝑙𝑙𝑙𝑙 can be
expressed as
𝐹𝐹𝑙𝑙𝑙𝑙 = 𝐹𝐹𝑣𝑣 󶀡󶀡1 − 𝜎𝜎𝑙𝑙󶀱󶀱 𝐶𝐶𝑙𝑙𝑙𝑙 + 𝑃𝑃𝑙𝑙
𝑆𝑆
𝑉𝑉
󶀢󶀢𝐶𝐶𝑙𝑙𝑙𝑙 − 𝐶𝐶𝑙𝑙𝑙𝑙󶀲󶀲
Pel
𝑙𝑙Pel − 1
,
𝐹𝐹𝑙𝑙𝑙𝑙 = 𝐹𝐹ly𝐶𝐶𝑙𝑙𝑙𝑙,
(22)
where 𝐶𝐶𝑙𝑙𝑙𝑙 is the concentration of liposome in blood plasma,
𝜎𝜎l is the osmotic re�ection coeﬃcient for the liposome
particles, and 𝑃𝑃l is the permeability of vasculature wall to
liposome. Pel is the transcapillary Peclet number de�ned as
Pel =
𝐹𝐹𝑣𝑣 󶀡󶀡1 − 𝜎𝜎𝑙𝑙󶀱󶀱
𝑃𝑃𝑙𝑙 (𝑆𝑆𝑆𝑉𝑉)
. (23)
e amount of released liposome encapsulated drug in the
interstitial �uid, 𝑆𝑆𝑟𝑟, is given by
𝑆𝑆𝑟𝑟 = 𝑘𝑘rel𝐶𝐶𝑙𝑙𝑙𝑙, (24)
where 𝑘𝑘rel is the release rate of liposome.
2.3.2. Free Doxorubicin Concentration in Blood Plasma (𝐶𝐶𝑓𝑓𝑙𝑙).
is is described by
𝜕𝜕𝐶𝐶𝑓𝑓𝑙𝑙
𝜕𝜕𝜕𝜕
= 𝑆𝑆𝑟𝑟 −
𝑉𝑉𝑇𝑇
𝑉𝑉𝐵𝐵
𝐹𝐹𝑓𝑓𝑙𝑙 −
𝐶𝐶𝐶𝐶𝑓𝑓𝑙𝑙𝐶𝐶𝑓𝑓𝑙𝑙
𝑉𝑉𝐷𝐷
− 󶀢󶀢𝑘𝑘𝑎𝑎𝐶𝐶𝑓𝑓𝑙𝑙 − 𝑘𝑘𝑑𝑑𝐶𝐶𝑏𝑏𝑙𝑙󶀲󶀲 ,
(25)
where 𝐹𝐹𝑓𝑓𝑙𝑙 represents the free doxorubicin crossing the
capillary wall into the interstitial �uid.𝑉𝑉𝑇𝑇 is tumour volume,
𝑉𝑉𝐵𝐵 is plasma volume, and 𝑉𝑉𝐷𝐷 is the volume of distribution,
which is a pharmacological theoretical volume that a drug
would have to occupy to provide the same concentration as
it is currently in blood plasma. 𝐶𝐶𝐶𝐶𝑓𝑓𝑙𝑙 is the plasma clearance
of drug. 𝑘𝑘𝑎𝑎 and 𝑘𝑘𝑑𝑑 are the association and disassociation rates
with proteins.
2.3.3. Bound Doxorubicin Concentration in Blood Plasma
(𝐶𝐶𝑏𝑏𝑙𝑙). is is described by
𝜕𝜕𝐶𝐶𝑏𝑏𝑙𝑙
𝜕𝜕𝜕𝜕
= 󶀢󶀢𝑘𝑘𝑎𝑎𝐶𝐶𝑓𝑓𝑙𝑙 − 𝑘𝑘𝑑𝑑𝐶𝐶𝑏𝑏𝑙𝑙󶀲󶀲 −
𝑉𝑉𝑇𝑇
𝑉𝑉𝐵𝐵
𝐹𝐹𝑏𝑏𝑙𝑙 −
𝐶𝐶𝐶𝐶𝑏𝑏𝑙𝑙𝐶𝐶𝑏𝑏𝑙𝑙
𝑉𝑉𝐷𝐷
, (26)
where 𝐶𝐶𝐶𝐶𝑏𝑏𝑙𝑙 is the plasma clearance of bound doxorubicin.
2.3.4. Free Doxorubicin Concentration in Interstitial Fluid
(𝐶𝐶𝑓𝑓𝑙𝑙). is is described by
𝜕𝜕𝐶𝐶𝑓𝑓𝑙𝑙
𝜕𝜕𝜕𝜕
+ ∇ ⋅ 󶀢󶀢𝐶𝐶𝑓𝑓𝑙𝑙𝐯𝐯󶀲󶀲 = 𝐷𝐷𝑓𝑓𝑙𝑙∇
2𝐶𝐶𝑓𝑓𝑙𝑙 + 𝑆𝑆𝑓𝑓. (27)
e source term 𝑆𝑆𝑓𝑓 is the net rate of doxorubicin gained from
the surrounding environment, which is given by
𝑆𝑆𝑓𝑓 = 𝑆𝑆𝑣𝑣 + 𝑆𝑆𝑏𝑏 + 𝑆𝑆𝑢𝑢 + 𝑆𝑆𝑟𝑟. (28)
Expressions for the terms on the right hand side have been
given previously (see (11)–(14) and (24)).
2.4. Pharmacodynamics Model. During anticancer treat-
ment, tumour cell density may change due to cell killing
as a result of drug eﬀect, tumour cell proliferation, and
physiological degradation. is can be described by a phar-
macodynamics model as given below:
𝑑𝑑𝐷𝐷𝑐𝑐
𝑑𝑑𝜕𝜕
= −
𝑓𝑓max𝐶𝐶𝑖𝑖
𝐸𝐸𝐶𝐶50 + 𝐶𝐶𝑖𝑖
𝐷𝐷𝑐𝑐 + 𝑘𝑘𝑙𝑙𝐷𝐷𝑐𝑐 − 𝑘𝑘𝑔𝑔𝐷𝐷
2
𝑐𝑐 . (29)
e �rst term on the right hand side represents the eﬀect
of anticancer drug, where 𝑓𝑓max is the cell-kill rate constant
and 𝐸𝐸𝐶𝐶50 is the drug concentration producing 50% of
𝑓𝑓max. 𝑘𝑘𝑙𝑙 and 𝑘𝑘𝑔𝑔 are cell proliferation rate constant and
physiologic degradation rate, respectively. In this study, cell
proliferation and physiologic degradation are assumed to
reach equilibrium at the beginning of each treatment.
2.5. Model Geometry. A 2D idealized model with a realistic
tumour size (Figure 1) is used in this study. e tumour
is located at the centre, which is surrounded by a layer of
normal tissue. e diameter of the tumour is 50mm, and the
thickness of the normal tissue is 10mm. ANSYS ICEM CFD
is used to create the geometry and generate the computational
mesh. e �nal mesh consists of 3922 triangular elements.
is is obtained based on mesh independence tests which
show that the diﬀerence in predicted drug concentration
between the adopted mesh and a 10-time �ner mesh is less
than 3%.
2.6. Model Parameters. Since the growth of tumour and
normal tissues is ignored, all the geometric and transport
parameters used in this study are assumed to be constant.
ese are summarized in Tables 1, 2, and 3 for parameters
related to the tissue, liposome, and doxorubicin, respectively.
2.6.1. Vascular Permeability. Vascular permeability coeﬃ-
cient measures the capacity of a blood vessel (oen capil-
lary in tumour) wall to allow for the �ow of substances,
typically nutrients or pharmaceutical agents in and out of
the vasculature. e permeability of polyethylene glycol
coated liposomes of 100 nm through tumour capillaries was
measured at 37∘C by Yuan et al. [23] and Wu et al. [24] as
2.0×10−10 and 3.42±0.78×10−9m/s, respectively. In normal
granulation tissues permeability of the same liposomes was
0.8 − 0.9 × 10−9m/s at the same temperature. Wu et al. [26]
also measured the permeability of albumin (corresponding
to albumin-bound doxorubicin) in tumour and granulation
tissues at 37∘C and obtained the values of 7.8 ± 1.2 × 10−9m/s
and 2.5 ± 0.8 × 10−9m/s, respectively. e mean values of the
above measurements are adopted in this study.
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T 1: Parameters for tumour and normal tissues (symbols are de�ned near the equations in which they �rst appear).
Parameter Unit Tumour Tissue Normal Tissue Reference
𝑆𝑆𝑆𝑆𝑆 m−1 20000 7000 [15–18]
𝐾𝐾𝑣𝑣 m/Pa⋅s 2.10 × 10−11 2.70 × 10−12 [15–18]
𝐾𝐾 m2/Pa⋅s 3.10 × 10−14 6.40 × 10−15 [15–18]
𝜌𝜌 kg/m3 1000 1000 [18]
𝜇𝜇 kg/m⋅s 0.00078 0.00078 [18]
1𝑆𝜅𝜅 m−2 4.56 × 1016 2.21 × 1017 [15–18]
𝑝𝑝𝑣𝑣 Pa 2080 2080 [15–18]
𝜋𝜋𝑣𝑣 Pa 2666 2666 [15–18]
𝜋𝜋𝑖𝑖 Pa 2000 1333 [15–18]
𝜎𝜎𝑇𝑇 0.82 0.91 [15–18]
𝐾𝐾ly𝑆𝑆ly𝑆𝑆𝑆 (Pa⋅s)−1 0 4.17 × 10−7 [18]
𝑝𝑝ly Pa 0 0 [18]
𝐷𝐷𝑐𝑐 105 cell/m3 1 × 1010 1 × 1010 [12, 22]
𝜑𝜑 0.4 — [12, 22]
T 2: Parameters for liposome (symbols are de�ned near the
equations in which they �rst appear).
Parameter Unit In tumour In normal Tissue Reference
𝑃𝑃𝑜𝑜 m/s 3.42 × 10−9 8.50 × 10−10 [23, 24]
ℎ 71 — —
𝐷𝐷 m2/s 9.0 × 10−12 5.8 × 10−12 [20, 23]
𝜎𝜎𝑙𝑙 0.95 1.0 —
𝐴𝐴1 kg/m3 6.90 × 10−3 6.90 × 10−3 [25]
𝐴𝐴2 kg/m3 8.37 × 10−5 8.37 × 10−5 [25]
𝑘𝑘1 s−1 1.22 × 10−2 1.22 × 10−2 [25]
𝑘𝑘2 s−1 4.17 × 10−6 4.17 × 10−6 [25]
𝑡𝑡ℎ hr 24 — —
𝑡𝑡𝑑𝑑 s 3600 — —
𝑘𝑘rel _37∘C s−1 0 — —
𝑘𝑘rel _42∘C s−1 0.0078 — —
Gaber et al. [5] noticed a 76-fold increase in the liposome
extracellular concentration on 45∘C heating. e permeabil-
ity to liposome at 42∘C can be estimated by interpolation,
which gives a 71-folder increase. Dalmark and Storm [40]
measured the permeability of free doxorubicin at various
temperatures, and their results showed that the permeability
to doxorubicin at 42∘C was 2.56-time higher at 37∘C. Hence,
temperature-dependent vascular permeability for both lipo-
some and doxorubicin is adopted to allow for enhanced
permeability at hyperthermia.
2.6.2. Re�e�tio� �oe��ie�t. e re�ection coeﬃcient deter-
mines the eﬃciency of the oncotic pressure gradient in
driving transport across the vascular wall. It is related to the
sizes of drug and pores on the vasculature wall [41]. For
the same drug, this parameter may vary in diﬀerent types of
tissues [42, 43].Wolf et al. [32]measured the re�ection coeﬃ-
cient for albumin and found this to be 0.82±0.08.e sizes of
albumin and liposome are 3.5 nm and 100 nm, respectively.
Tumour tissue
Normal tissue
1 cm
F 1: Model geometry.
e re�ection coeﬃcient for liposome is estimated to be
greater than 0.90; hence it is assumed to be 0.95 in this study.
Because the size of liposome is much larger than the pore
size on the vasculature wall in normal tissues (24–60 nm in
diameter [44]), the re�ection coeﬃcient in normal tissue is
assumed to be 1.0.
2.6.3. Liposome Release Rate (𝑘𝑘𝑟𝑟𝑟𝑟𝑙𝑙). ermosensitive lipo-
some is designed to release its contents rapidly on heating
[6]. e release rate varies according to the composition of
liposome, its preparation procedure, and heating temperature
[45]. e relation between percentage release and exposure
time is found to follow the �rst-order kinetics expressed as
[46]
%𝑅𝑅 (𝑡𝑡) = 𝑅𝑅𝑐𝑐 󶀢󶀢1 − 𝑟𝑟
−𝑘𝑘rel𝑡𝑡󶀲󶀲 , (30)
where %𝑅𝑅(𝑡𝑡) is the percentage of drug released at exposure
time 𝑡𝑡; 𝑅𝑅𝑐𝑐 is the total percentage of drug released at a
given heating temperature. is equation is used to �t the
experimental data obtained at 42∘C [45]. From the best �tting
curve (shown in Figure 2) obtained by using nonlinear least-
squares method, the release rate is found to be 0.0078. At
6 Journal of Drug Delivery
T 3: Parameters for doxorubicin (symbols are de�ned near the equations in which they �rst appear).
Parameter Unit Free doxorubicin Bound doxorubicin Reference
𝑃𝑃Tumour_𝑜𝑜 m/s 3.00 × 10−6 7.80 × 10−9 [18, 26]
ℎ 2.56 — —
𝑃𝑃Normal m/s 3.75 × 10−7 2.50 × 10−9 [18, 26]
𝐷𝐷Tumour m2/s 3.40 × 10−10 8.89 × 10−12 [18, 22, 27–31]
𝐷𝐷Normal m2/s 1.58 × 10−10 4.17 × 10−12 [18, 22, 27–31]
MW kg/mol 0.544 69.0 [12, 18]
𝜎𝜎𝑑𝑑 0.15 0.82 [18, 32]
𝑘𝑘𝑎𝑎 s−1 0.833 — [22]
𝑘𝑘𝑑𝑑 s−1 — 0.278 [22]
𝑉𝑉max kg/105 cells s 4.67 × 10−15 — [22, 33]
𝑘𝑘𝑒𝑒 kg/m3 2.19 × 10−4 — [22, 33]
𝑘𝑘𝑖𝑖 kg/m3 1.37 × 10−12 — [22, 33]
𝑘𝑘max s−1 1.67 × 10−5 — [34]
EC50 kg/105 cells 5 × 10−13 — [34]
𝐷𝐷 kg 8.56 × 10−5 — [1]
𝐴𝐴 m−3 74.6 74.6 [22, 35]
𝐵𝐵 m−3 2.49 2.49 [22, 35]
𝐶𝐶 m−3 0.552 0.552 [22, 35]
𝛼𝛼 s−1 2.43 × 10−3 2.43 × 10−3 [22, 35]
𝛽𝛽 s−1 2.83 × 10−4 2.83 × 10−4 [22, 35]
𝛾𝛾 s−1 1.18 × 10−5 1.18 × 10−5 [22, 35]
𝑘𝑘𝑝𝑝 s−1 3.0 × 10−6 — [36]
𝑘𝑘𝑔𝑔 s−1 3.0 × 10−16 — [36]
CLtumour s−1 1.48 × 10−5 0 [35, 37–39]
CLtumour s−1 2.43 × 10−3 0 [35, 37–39]
Experimental data [31]
Fitting curve
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F 2: Liposome release rate at 42∘C.
normal physiological temperature of 37∘C, there should be no
release; hence the release rate at 37∘C is assumed to be zero.
2.6.4. Plasma Pharmacokinetics
(1) Direct Continuous Infusion. e doxorubicin concentra-
tion in blood plasma is modelled as an exponential decay
function of time. e form of equation depends on the infu-
sion mode. For continuous infusion, a triexponential decay
function is assumed based on the plasma pharmacokinetics
of doxorubicin:
𝐶𝐶𝑣𝑣 =
𝐷𝐷
𝑇𝑇
󶁥󶁥󶀥󶀥
𝐴𝐴
𝛼𝛼
󶀢󶀢1 − 𝑒𝑒−𝛼𝛼𝛼𝛼󶀲󶀲 +
𝐵𝐵
𝛽𝛽
󶀢󶀢1 − 𝑒𝑒−𝛽𝛽𝛼𝛼󶀲󶀲 +
𝐶𝐶
𝛾𝛾
󶀢󶀢1 − 𝑒𝑒−𝛾𝛾𝛼𝛼󶀲󶀲󶀲󶀲󶀲󶀲
(𝛼𝛼 𝑡 𝑇𝑇) ,
𝐶𝐶𝑣𝑣 =
𝐷𝐷
𝑇𝑇
󶁥󶁥
𝐴𝐴
𝛼𝛼
󶀢󶀢𝑒𝑒𝛼𝛼𝑇𝑇 − 1󶀲󶀲 𝑒𝑒−𝛼𝛼𝛼𝛼 +
𝐵𝐵
𝛽𝛽
󶀢󶀢𝑒𝑒𝛽𝛽𝑇𝑇 − 1󶀲󶀲 𝑒𝑒−𝛽𝛽𝛼𝛼
+
𝐶𝐶
𝛾𝛾
󶀢󶀢𝑒𝑒𝛾𝛾𝛼𝛼 − 1󶀲󶀲 𝑒𝑒−𝛾𝛾𝛼𝛼󶀲󶀲 (𝛼𝛼 𝑡 𝑇𝑇) ,
(31)
where 𝐷𝐷 is the dose of doxorubicin and 𝑇𝑇 is the infusion
duration. 𝐴𝐴, 𝐵𝐵, and 𝐶𝐶 are compartment parameters and 𝛼𝛼,
𝛽𝛽, 𝛾𝛾 are compartment clearance rates.
Free doxorubicin in plasma can easily bind with proteins,
such as albumin. Greene et al. [13] found that 74%–82% is
present in the formof bound doxorubicin, and the percentage
is independent of doxorubicin and albumin concentrations.
Hence for direct infusion, the free (𝐶𝐶𝑓𝑓𝑝𝑝) and bound (𝐶𝐶𝑏𝑏𝑝𝑝)
doxorubicin in plasma are given by
𝐶𝐶𝑓𝑓𝑝𝑝 = (1 − 𝑠𝑠) 𝐶𝐶𝑣𝑣; 𝐶𝐶𝑏𝑏𝑝𝑝 = 𝑠𝑠𝐶𝐶𝑣𝑣, (32)
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where 𝑠𝑠 is the percentage of bound doxorubicin, which is 0.75
in this study.
(2) ermosensitive Liposome-Mediated Drug Release. e
liposome encapsulated doxorubicin concentration in blood
plasma is found to follow a 2-exponential decaying function
of time [13], written as
𝐶𝐶𝑙𝑙𝑙𝑙 = 𝐴𝐴1𝑒𝑒
−𝑘𝑘1𝑡𝑡 + 𝐴𝐴2𝑒𝑒
−𝑘𝑘2𝑡𝑡, (33)
where 𝐴𝐴1 and 𝐴𝐴2 are compartment parameters, and 𝑘𝑘1 and
𝑘𝑘2 are compartment clearance rates.
2.7. Boundary Conditions. Because the time scale for the
simulation is assumed to be short enough to ignore the
growth of tumour and normal tissues, the interface between
the tumour and normal tissue as well as the outer surface of
normal tissue are �xed.e interface between the tumour and
normal tissues is treated as an internal boundary where all
variables are continuous. e relative pressure at the outer
surface of normal tissues is assumed to be constant at 0 Pa,
where �ero �ux of drug is also speci�ed.
2.8.NumericalMethods. emathematicalmodels described
above are implemented into ANSYS FLUENT, which is a
�nite volume based computational �uid dynamics (CFD)
code. Mass transfer equations describing the transport of
drugs are coded by using the User De�ned Scalar (known
as UDS). ese equations are solved in conjunction with
the continuity and momentum equations using numerical
algorithms available in FLUENT. Spatial discretisation is
performed by employing the second orderUPWIND scheme,
while pressure-velocity coupling is achieved by the SIM-
PLEC algorithm.e absolute criteria for residual tolerances
for solutions of the Navier-Stokes equations and the drug
transport equations are 1 × 10−5 and 1 × 10−8, respectively.
e equations for the interstitial �uid �ow are solved �rst
to obtain a steady-state solution in the entire tumour and
its surrounding normal tissues. e obtained pressure and
velocity �elds are then applied to the equations for drug
transport. e second-order implicit backward Euler scheme
is used for temporal discretisation, and a �xed time step si�e
of 10 seconds is chosen, which is obtained aer time-step
sensitivity tests.
3. Results and Discussion
e microenvironment in tumour and normal tissues plays
an important role in determining the eﬃciency of liposome
and drug transport. e interstitial �uid pressure (IFP)
determines the drug exchange between interstitial �uid and
blood plasma, as well as tumour and normal tissues. e
mean IFP predicted in the tumour region is 1533 Pa, which
is almost identical to the value reported by Baxter and Jain
[15]. e mean IFP in the normal tissue is 41 Pa.
e spatial distribution of IFP in tumour and normal
tissues is shown in Figure 3. It is clear that pressures in the
tumour and normal tissues are at diﬀerent levels, and a thin
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F 3: Interstitial �uid pressure distribution in tumour and
normal tissues.
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F 4: Liposome concentration in plasma and interstitial �uid as
a function of time aer start of treatment (dose = 50mg/m2).
layer of steep pressure gradient exists at the interface between
the two regions.
Liposome encapsulated doxorubicin concentration is a
key parameter that determines the doxorubicin concentra-
tion in tumour cells. Shown in Figure 4 are the predicted
time courses of liposome encapsulated doxorubicin concen-
trations in blood plasma and interstitial space in tumour
and normal tissues, for a total doxorubicin dose of 50mg/m2
encapsulated in thermosensitive liposomes.
Liposome encapsulated doxorubicin is administrated
into blood in a very short duration, and its concentration
in plasma decreases following an exponential decay function
of time during the entire treatment period [13]. Its concen-
tration in tumour increases rapidly in the initial stage aer
administration. is is because at this stage, the concentra-
tion in plasma is much higher than that in tumour, providing
the driving force for liposome to pass through the vasculature
wall and accumulate in tumour.e concentration in tumour
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F 5: Spatial distribution of liposome encapsulated doxorubicin extracellular concentration in tumour and normal tissues.
reaches its peakwhen the concentration in tumour interstitial
�uid and plasma reaches an e�uilibrium state. Upon heating
at 24 hours aer administration (heating lasts for 1 hour),
doxorubicin is rapidly released from liposome, resulting in
a sharp fall in the concentration of liposome encapsulated
doxorubicin in the interstitial �uid of tumour, followed by a
steady increase aer heating ceases at 25 hour.
Since the size of liposome is too large to pass through
the vasculature wall in normal tissues [44, 45], liposome
encapsulated doxorubicin enters normal tissues by diﬀusion
and convection from tumour, which can be seen clearly in
Figure 5. is is the reason why the liposome encapsulated
doxorubicin concentration in normal tissues increases slowly
over time and stays at a very low level during the simulation
time.
ere is evidence for rapid and signi�cant binding
between free doxorubicin and proteins in plasma [12, 22].
Predicted free and bound doxorubicin concentrations in
plasma for thermosensitive liposome delivery and 2-hour
infusion of nonencapsulated doxorubicin are compared in
Figure 6. Results show that 75% doxorubicin binds with
proteins, which is consistent with the experimental data of
Greene et al. [13].
For direct infusion of nonencapsulated doxorubicin, the
infusion duration is 2 hours as recommended in the literature
[12], and the total dose is 50mg/m2.e free and bound dox-
orubicin concentrations increase rapidly during the initial
period following drug administration. For thermosensitive
liposome delivery, the doxorubicin concentration remains
at zero in the �rst 24 hours, since no doxorubicin is
released from liposome before heating is applied. Upon
heating to mild hyperthermia at 24 hours which lasts for
one hour, doxorubicin is rapidly released from liposome
causing much higher concentration in plasma. Because
the temperature of tumour falls back to 37∘C immediately
aer heating is stopped and assuming that encapsulated
doxorubicin remains trapped within the core of liposome,
the concentration declines rapidly to a low level. Although
the concentration with both modes of administration drops
to a low level aer the infusions ends, 2-hour continuous
infusion of nonencapsulated doxorubicin gives a slightly
higher concentration over time.
Free and bound extracellular concentrations of doxoru-
bicin in tumour and normal tissues are shown in Figures
7 and 8, respectively. Comparing the extracellular concen-
trations in these two �gures with the plasma concentration
in Figure 6, they all seem to follow the same trend. is
means that plasma concentration has a direct in�uence
on the extracellular concentration of both free and bound
doxorubicin.
Despite thermosensitive liposome delivery gives higher
peak values for both free and bound extracellular concen-
trations of doxorubicin in normal tissues, the concentration
level is still lower than the half maximal (50%) inhibitory
concentration (IC) of doxorubicin in normal tissue, which
is 4.13 × 10−5 kg/m3 [47]. However, the rate of cell killing
is found to be related to the area under the extracellular
concentration curve (AUC𝑒𝑒) [48, 49]. A simpli�ed model
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(b)
F 6: Spatial mean free (a) and bound (b) doxorubicin plasma concentration in tumour as a function of time under liposome delivery
and 2-hr infusion of nonencapsulated doxorubicin (dose = 50mg/m2).
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(b)
F 7: Spatial mean free and bound doxorubicin extracellular concentration in tumour as a function of time under thermosensitive
liposome delivery and 2-hour infusion (dose = 50mg/m2).
in literature [49] shows that the logarithmic value of cell
survival fraction is proportional to the AUC𝑒𝑒. Values for
AUC𝑒𝑒 under 2-hour infusion and thermosensitive liposome
delivery are compared in Table 4 which shows that the 2-
hour infusion leads to high AUC𝑒𝑒 in the �rst 4� hours
of the treatment, suggesting that 2-hour direct infusion of
doxorubicin is likely to cause more cell death in normal
tissues than thermosensitive liposome delivery.
Because heating can be controlled and localised in
tumour, the temperature in normal tissues would be lower
than the hyperthermia temperature required for the release
of doxorubicin from liposomes. During the heating period,
doxorubicin enters normal tissue only by diﬀusion and
convection from tumour. is leads to doxorubicin being
T 4: AUC𝑒𝑒 with various drug delivery modes in the �rst 4�
hours.
Free AUC𝑒𝑒 (kgs/m3) Bound AUC𝑒𝑒 (kgs/m3)
Liposome delivery 1.59 × 10−6 5.19 × 10−6
2-hour infusion 2.30 × 10−6 6.91 × 10−6
mainly concentrated in the region surrounding the tumour,
as shown in Figure 9(b). However, under 2-hour direct
infusion, doxorubicin is carried by blood into normal tis-
sues. is leads to doxorubicin concentration reaching a
higher level in the entire region of normal tissues, shown in
Figure 9(a). Hence, thermosensitive liposome-mediated drug
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F 8: Spatial mean free and bound doxorubicin extracellular concentration in normal tissue as a function of time under thermosensitive
liposome delivery and 2-hour infusion of nonencapsulated doxorubicin (dose = 50mg/m2).
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F 9: Spatial distribution of free doxorubicin extracellular concentration in normal tissues at 25-hour with 2-hour infusion and liposome
delivery (dose = 50mg/m2).
delivery performs better in reducing drug concentration in
the main region of normal tissues, which may help lower the
risks of associated side eﬀects.
Figure 10 presents the intracellular doxorubicin con-
centration in tumour for thermosensitive liposome delivery
and 2-hour direct infusion. e intracellular concentration
under 2-hour direct infusion displays a quick rise aer drug
administration until it reaches a peak and then decreases.e
intracellular concentration under thermosensitive liposome
delivery remains at zero until 24 hours, but there is a sharp
rise to a high peak immediately aer heating. However,
as heating ceases and tumour tissue cools down to the
physiological temperature range, no new doxorubicin is
released and the intracellular concentration drops rapidly
to a low level. Compared with 2-hour direct infusion, the
thermosensitive liposome delivery leads to a much higher
peak intracellular concentration.
Compared with the study reported by El-Kareh and
Secomb [12], lower free doxorubicin extracellular and intra-
cellular concentrations are found here. is is because the
present model accounts for the eﬀect of binding between
doxorubicin and proteins in plasma. Since 75% doxorubicin
is bound with proteins, less free doxorubicin is available in
plasma for crossing the vasculature wall and entering the
interstitial space, which leads to less drug uptake by tumour
cells. Together with the experimental evidence [13], our
predictions demonstrate that protein binding of anticancer
drugs in plasma is an important factor that should be
included in future mathematical models.
Figure 11 shows the fraction of survival cells by applying
the pharmacodynamics model described by (29). As can
be observed, the therapeutic eﬀectiveness of 2-hour direct
infusion can last for a longer period aer administration.
Fewer tumour cells are killed aer 36 hours because the
Journal of Drug Delivery 11
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intracellular concentration is below the threshold for cell
killing (Figure 10). On the other hand, the eﬀect of ther-
mosensitive liposome delivery takes place aer the start of
heating. Highly eﬀective tumour cell killing is observed since
the intracellular concentration rises to a very high level
in a short period of time (Figure 10). However, because
temperature drops to the normal physiological range aer
heating, and no doxorubicin is released at this temperature,
both the extra- and intracellular concentrations fall rapidly
to a low level (Figures 7 and 10). Since the rate of cell
killing caused by doxorubicin is slower than the rate of
cell proliferation, the survival faction starts to rise aer 34
hours. Nevertheless, thermosensitive liposome delivery leads
to higher tumour cell death in a shorter time period than 2-
hour direct infusion. On the other hand, the 2-hour direct
infusion yields a higher extracellular concentration in normal
tissues, which is undesirable as high drug concentration in
normal tissue may increase the risk of side eﬀects in patients.
Although the present numerical study oﬀers some new
insight into how anticancer treatment eﬃcacy could be
aﬀected by diﬀerent drug delivery modes, the mathematical
models involve a number of assumptions. For example,
realistic changes in tumour temperature during heating and
aer heating are ignored, and step changes are speci�ed
instead. In clinical practice, tumour temperature pro�les
(temperature versus time curve) may vary depending on the
heating method applied. Moreover, temperature distribution
in tumour tissue is likely to be nonuniform. ese factors
can in�uence the outcome of anticancer treatments. Other
assumptions include an idealised geometry for the tumour
and normal tissues, uniform transport properties, and a
uniform distribution of microvasculature for administration
of anticancer drug.
4. Conclusion
Doxorubicin delivery into solid tumour by direct continu-
ous infusion and thermosensitive liposome are studied by
mathematical modelling, and the anticancer eﬀectiveness
is evaluated in terms of the survival fraction of tumour
cells. Our computational results show that thermosensitive
liposome-mediated delivery oﬀers a lower drug concentra-
tion in normal tissues than direct infusion of nonencap-
sulated doxorubicin, which may help reduce the risk of
associated side eﬀects. In addition, thermosensitive liposome
delivery achieves a signi�cantly higher peak intracellular
concentration, and hence more rapid and eﬀective tumour
cell killing in a short time period of treatment.
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